Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

  • Technology appraisal guidance
  • TA308
  • Published: 

History

Documents created during the development process.

Review proposal consultation

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): Equality Impact Assessment - guidance development

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): final appraisal determination

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): appraisal consultation 2

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids): appraisal consultation

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with corticosteroids: equality impact assessment - scoping

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with corticosteroids: response to consultee and commentator comments on the draft scope and provisional matrix

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with corticosteroids: final matrix

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with corticosteroids): final scope